Adult adherent stromal cells in the management of graft-versus-host disease

Abstract

Introduction: Early reports demonstrated the safety of adherent mesenchymal stromal cell (MSC) infusions in the hematopoietic stem cell transplantation (HCT) setting, as well as clinical efficacy for treatment of steroid refractory acute graft-versus-host disease (GVHD); however, two large, Phase III randomized, placebo-controlled trials of MSC for initial therapy or steroid refractory GVHD failed to meet their primary endpoints of durable complete response. Subset analyses demonstrated efficacy in selected patient populations, contributing to recent approvals of MSC for pediatric patients in Canada and New Zealand.

Areas covered: In this review, we discuss the biologic and immunomodulatory properties of MSC and potential mechanisms involved. We review the results of prior clinical trials incorporating MSC for GVHD treatment or prophylaxis, the recent approvals in Canada and New Zealand, as well as future directions in the field.

Expert opinion: The role of MSC infusions, in the prophylaxis and/or treatment of GVHD after HCT, continues to be under active investigation. Whether, and how, to incorporate MSC infusions is unclear, and ongoing questions include the source tissue type and culture methods, the timing and dosage of MSC product infusions, as well as the optimal clinical trial design and endpoints for assessment of clinical response.

Keywords::

• graft-versus-host disease
• hematopoietic stem cell transplantation
• mesenchymal stromal cells

Declaration of interest

LF Newell has no disclosures. RJ Deans is a paid employee and share option holder of Athersys, Inc. RT Maziarz is a recipient of a research grant from Athersys, Inc. Additionally, Athersys has licensed technology from OHSU of which RT Maziarz and RJ Deans are co-inventors. This potential individual and institutional conflict-of-interest has been reviewed and managed by OHSU.

Notes

This box summarizes key points contained in the article.